Conversion of psoriasis patients from the conventional formulation of cyclosporin A to a new microemulsion formulation: A randomized, open, multicentre assessment of safety and tolerability

Dermatology

Volumn 196, Issue 2, 1998, Pages 231-236

  Zachariae, H ^a,b   Abrams, B ^a   Bleehen, S S ^a   Brautigam M ^a   Burrows, D ^a   Ettelt, M J ^a   Fry, L ^a   Happle, R ^a   Haustein, U F ^a   Ganslandt, J ^a   Jung, E G ^a   Knop, J ^a   Kuhne K H ^a   Mellein, B ^a   Mork N J ^a   Rogers, S ^a   Schmidt, A G ^a   Schopf, R E ^a   Sumner, M ^a   Taube, K M ^a   Weidinger, G ^a   Wurdel, C ^a   Zahn, E ^a   more..

^a NONE

^b Ildervej 40   (Denmark)

Author keywords

Cyclosporin A; Microemulsion formulation; Psoriasis

Indexed keywords

CREATININE; CYCLOSPORIN A;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DISEASE SEVERITY; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; LEG EDEMA; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; MENORRHAGIA; MICROEMULSION; MULTICENTER STUDY; NEPHROLITHIASIS; ORAL DRUG ADMINISTRATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSORIASIS; SIDE EFFECT;

EID: 0031933038     PISSN: 10188665     EISSN: None     Source Type: Journal    
DOI: 10.1159/000017880     Document Type: Article

References (6)

1. Faulds D, Goa KL, Benfield P: Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders. Drugs 1993;45:953-1040.
2. Johnston A: The relationship between Neoral® pharmacokinetics and meaningful clinical benefits. International Congress on Immunointervention: The role of Neoral® in Immune-Based Diseases. Rome, Blackwell Healthcare Communications, 1996, pp 22-23.
3. Elder CA, Moore M, Chang C-T, Jin J, Charnick S, Nedelman J, Cohen A, Guzzo C, Lowe N, Simpson K, Karara AH, Meligeni J: Efficacy and pharmacokinetics of two formulations of cyclosporine A in patients with psoriasis. J Clin Pharmacol 1995;35:865-875.
4. Finzi AF, Della Casa-Alberighi O: The place of cyclosporin in the treatment of severe psoriasis. Clin Drug Invest 1995;10:45-52.
5. Berth-Jones J, Voorhees JJ: Consensus conference on cyclosporin A microemulsion for psoriasis, June 1996. Br J Dermatol 1996;135:775-777.
6. Mihatsch MJ, Wolff K: Consensus conference on cyclosporin A for psoriasis, February 1992. Br J Dermatol 1992;126:621-623.